Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND WITH OVERWEIGHT OR OBESITY: A TARGET TRIAL EMULATION STUDY
ÌÇÐÄ´«Ã½
EFFECT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS ON METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND WITH OVERWEIGHT OR OBESITY: A TARGET TRIAL EMULATION STUDY Nguyen, M., Mao, X., Zhang, X., Lai, R., Yuen, M., Cheung, R., Cheung, K., Seto, W. LIPPINCOTT WILLIAMS & WILKINS. 2024: S885-S886View details for